Clinical Research Is Booming In India But Are There Enough IRBs?
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Over the past decade, India's clinical research industry has grown at a compound annual rate of 64 percent, zooming up from just $12 million in 2001 to an estimated billion-plus dollars by next year. But that meteoric rise may be putting pressure on Institutional Review Boards entrusted with approval of clinical trials and some industry experts are now asking for better controls over IRBs, or ethics review boards
You may also be interested in...
India Mulls Laws To Accredit Ethics Committees To Streamline Clinical Trials
The government is looking to tighten laws that would make ethics committees more accountable
Pfizer, Lilly, Sanofi, Amgen And Others Named In Indian Clinical Trial Death Compensation Inquiry
The news of the health ministry probe earlier this month stirred debate about the gaping holes in Indian clinical trial laws and the country's loose enforcement framework, particularly as clinical trial projects flow rapidly into the country.
Pfizer, Lilly, Sanofi, Amgen And Others Named In Indian Clinical Trial Death Compensation Inquiry
The news of the health ministry probe earlier this month stirred debate about the gaping holes in Indian clinical trial laws and the country's loose enforcement framework, particularly as clinical trial projects flow rapidly into the country.